Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Jungle Olive (Olea europaea) fruit extract contains high concentrations of oleuropein and hydroxytyrosol, which inhibit BACE-1 enzyme activity and modulate amyloid precursor protein processing to reduce neuroinflammation. These secoiridoid compounds also downregulate the NF-κB pathway and suppress pro-inflammatory mediators like COX-2 and IL-8 in immune cells.
Reported Benefits (Provisional)
Origin & History
Jungle Olive, a tropical fruit, originates from diverse rainforest regions across Southeast Asia, Central and South America, and Africa. It is prized for its unique fatty acid profile and rich antioxidant content. This fruit offers significant potential for functional nutrition, particularly for cardiovascular and cognitive health.
Research Narrative (Provisional)
Emerging research, including in vitro and animal studies, highlights Jungle Olive's potential for cardiovascular protection, cognitive support, and antioxidant activity, largely attributed to its unique fatty acid and polyphenol content. While traditional uses are well-established, further human clinical trials are needed to confirm these benefits and determine optimal dosages.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Monounsaturated fats (oleic acid) - Vitamin E - Magnesium - Potassium - Iron - Polyphenols - Flavonoids - Squalene
Reported Mechanism (Provisional)
The primary bioactive oleuropein inhibits BACE-1 enzyme, reducing amyloid-β production while increasing anti-amyloidogenic sAPPα and α-secretase activity. Hydroxytyrosol and verbascoside suppress NF-κB pathway activation, downregulating NLRP3, RAGE/HMGB1, and inflammatory cytokines. These compounds enhance clearance proteins P-gp and LRP1 while reducing soluble Aβ40 levels and plaque formation.
Clinical Narrative (Provisional)
Current evidence consists primarily of in vitro and animal studies demonstrating reduced amyloid-β plaque size and inflammatory marker suppression in Alzheimer's disease models. Preclinical research shows downregulated COX-2 and IL-8 expression in peripheral blood mononuclear cells, but no quantified human clinical trial data with specific dosages, patient cohorts, or statistical outcomes exists. The cardiovascular and neuroprotective claims require validation through randomized controlled trials with defined endpoints. Traditional use provides safety precedent, but clinical efficacy remains unestablished in human populations.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.